Skip to main content

Table 2 Baseline characteristics of patients in three independent validation cohorts

From: Development and validation of a hypoxia-immune-based microenvironment gene signature for risk stratification in gastric cancer

Characteristics Whole cohort Low risk High risk p
TCGA cohort (n = 321) (n = 78) (n = 243)  
Gender 0.772
 Male 204 (63.55) 48 (61.54) 156 (64.20)  
 Female 117 (36.45) 30 (38.46) 87 (35.80)  
Age 0.995
 < 65 years 146 (45.48) 36 (46.15) 110 (45.27)  
 ≥ 65 years 175 (54.52) 42 (53.85) 133 (54.73)  
TNM stagea 0.253
 I 44 (13.71) 13 (16.67) 31 (12.76)  
 II 104 (32.40) 18 (23.08) 86 (35.39)  
 III 132 (41.12) 36 (46.15) 96 (39.51)  
 IV 29 (9.03) 7 (8.97) 22 (9.05)  
WHO classification 0.085
 Intestinal/tubular 125 (38.94) 34 (43.59) 91 (37.45)  
 Diffuse 57 (17.76) 15 (19.23) 42 (17.28)  
 Mucinous/signet ring cell 26 (8.10) 1 (1.28) 25 (10.29)  
 Others 113 (35.20) 28 (35.90) 85 (34.98)  
ACRG cohort (n = 300) (n = 219) (n = 81)  
Gender 0.950
 Male 199 (66.33) 146 (66.67) 53 (65.43)  
 Female 101 (33.67) 73 (33.33) 28 (34.57)  
Age 0.999
 < 65 years 161 (53.67) 118 (53.88) 43 (53.09)  
 ≥ 65 years 139 (46.33) 101 (46.12) 38 (46.91)  
TNM stage 0.097
 I 30 (10.00) 27 (12.32) 3 (3.70)  
 II 97 (32.33) 73 (33.33) 24 (29.63)  
 III 96 (32.00) 67 (30.59) 29 (35.80)  
 IV 77 (25.67) 52 (23.74) 25 (30.86)  
Lauren classification 0.141
 Diffuse 135 (45.00) 91 (41.55) 44 (54.32)  
 Intestinal 146 (48.67) 113 (51.60) 33 (40.74)  
 Mixed 19 (6.33) 15 (6.84) 4 (4.93)  
CHEM cohort (n = 136) (n = 46) (n = 90)  
Gender 0.709
 Male 93 (68.38) 30 (65.22) 63 (70.00)  
 Female 43 (31.62) 16 (34.78) 27 (30.00)  
Age 0.726
 < 65 years 87 (63.97) 28 (60.87) 59 (65.56)  
 ≥ 65 years 49 (36.03) 18 (39.13) 31 (34.44)  
TNM stage 0.496
 II 36 (26.47) 15 (32.61) 21 (23.33)  
 III 63 (46.32) 19 (41.30) 44 (48.89)  
 IV 37 (27.21) 12 (26.09) 25 (27.78)  
Lauren classificationa 0.075
 Diffuse 30 (22.06) 15 (32.61) 15 (16.67)  
 Intestinal 95 (69.85) 27 (58.70) 68 (75.56)  
 Mixed 7 (5.15) 3 (6.52) 4 (4.44)  
  1. aTwelve patients with unavailable stage information in the TCGA cohort and four patients with unavailable Lauren classification information in the CHEM cohort were excluded from the comparison